Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Diversified Royalty Acquired the Trademarks and Some Other Intellectual Property Used by Cheba Hut Franchising for $36M and Additional Consideration; Adds Ninth Royalty Stream and Second Based in U.S.

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...

Post-Partum Depression Market Size | Drug Pipeline Analysis, Treatment, Trends, and Rising Global Prevalence 2025-2035 The report provides a detailed analysis of the current post-partum depression ...

Hospitals, physician groups, and nursing homes across 15 states will receive billions of dollars in extra Medicaid funding ...

Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion ...

I went through every mainline Zelda title to figure out just how much screentime the princess actually gets. That means ...